Last reviewed · How we verify
HSV formulation 2 with adjuvant 1 — Competitive Intelligence Brief
phase 1
Biologic
Live · refreshed every 30 min
Target snapshot
HSV formulation 2 with adjuvant 1 (HSV formulation 2 with adjuvant 1) — GlaxoSmithKline.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| HSV formulation 2 with adjuvant 1 TARGET | HSV formulation 2 with adjuvant 1 | GlaxoSmithKline | phase 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- HSV formulation 2 with adjuvant 1 CI watch — RSS
- HSV formulation 2 with adjuvant 1 CI watch — Atom
- HSV formulation 2 with adjuvant 1 CI watch — JSON
- HSV formulation 2 with adjuvant 1 alone — RSS
Cite this brief
Drug Landscape (2026). HSV formulation 2 with adjuvant 1 — Competitive Intelligence Brief. https://druglandscape.com/ci/hsv-formulation-2-with-adjuvant-1. Accessed 2026-06-10.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing